Search Results
Nov 17, 2025, 11:57 ET Resolve Therapeutics to Present at International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS)
active human RNase fused to an engineered Fc domain of human IgG1. It is designed to remain in circulation and digest extracellular pathogenic cell-free RNA (cfRNA) in diseases where the presence of cfRNA drives the inflammatory process. In contrast to immunosuppressive therapies that deplete the immune system
More news about: Resolve Therapeutics, LLC
Nov 17, 2025, 08:01 ET TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17,
More news about: TransCode Therapeutics, Inc.
Nov 14, 2025, 10:23 ET LAST CALL: Join Nobel Laureate & Global Leaders to Explore the Next Era of Cell & Gene Therapy in London
in Molecular Medicine, co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School, is best known for his co-discovery of RNA interference (RNAi), a breakthrough that transformed genetic research and paved the way for RNA-based medicines. On the topic of "RNAi:
More news about: GenScript Biotech Corporation
Nov 14, 2025, 10:01 ET Cardiovascular Biologics Market Expected to Reach USD 4.23 Billion by 2033 Amid Advances in RNA and Biologic Therapies | DataM Intelligence
programs. U.S. federal R&D grants for biologic drug development exceeded USD 1.1 billion in 2024, emphasizing RNA-based innovation and atherosclerosis immunotherapy. Japan
More news about: DataM Intelligence 4 Market Research LLP
Nov 14, 2025, 06:00 ET OUTFRONT XLabs Teams with Google DeepMind for First-of-its-Kind GenAI + Human-Led Campaign
Transformers - neural networks that underpin all modern language models, AlphaFold - an AI model that can accurately predict the structure of proteins, DNA, RNA, ligands and more, and how they interact, and Gemini, a family of versatile AI models built from the ground up for multimodality, seamlessly combining
More news about: OUTFRONT Media Inc.
Nov 13, 2025, 16:01 ET Co-Diagnostics Reports Third Quarter 2025 Financial Results
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Nov 13, 2025, 11:07 ET Immune Reactions Found Behind Human Rejection of Transplanted Pig Kidneys
damaging the transplanted pig kidney, they next plan to investigate what molecules the immune response is targeting through the different layers of DNA, RNA, and protein datasets generated. Keating says future studies in other human decedents and in live patients are needed to confirm
More news about: NYU Grossman School of Medicine and NYU Langone Health
Nov 13, 2025, 10:15 ET Next Generation Sequencing (NGS) Market Poised to Hit $42.25 Billion by 2033: Key Drivers Behind the Surge - Latest Study by Grand View Research, Inc.
Targeted Sequencing & Resequencing DNA-based RNA-based Others Next Generation Sequencing
More news about: Grand View Research, Inc.
Nov 13, 2025, 10:00 ET New England Biolabs® launches the NEBNext® Flu A Integrated Indexing Primer Module to advance Influenza A surveillance and sequencing
includes reagents for indexed cDNA synthesis, amplification, and library preparation, and it works seamlessly with NEB's Monarch® Mag Viral DNA/RNA Extraction Kit, LunaScript® Multiplex One-Step RT-PCR Kit, and ONT's Native Barcoding Workflow. The protocol was proactively released on protocols.io
More news about: New England Biolabs, Inc.
Nov 13, 2025, 09:00 ET Foundation Fighting Blindness Provides Public Access to Data From Its RUSH2A Natural History Study
We are proud to partner with the Foundation Fighting Blindness in leveraging the RUSH2A data to drive forward our USH2A program and bring innovative RNA therapies to the community as quickly and effectively as possible." RUSH2A has followed more than 100 USH2A patients for
More news about: Foundation Fighting Blindness
Nov 13, 2025, 07:00 ET Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the
More news about: Insmed Incorporated
Nov 12, 2025, 09:00 ET Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Nov 12, 2025, 08:00 ET Genezen Announces Manufacturing Partnership with Humane Genomics to Advance Oncolytic Virus Therapy for Pediatric Liver Cancer
synthetic RNA virus platform to rapidly design and engineer RNA viruses with precise anti-cancer capabilities. Through a two-factor selectivity mechanism, these therapies infect and replicate
More news about: Genezen
Nov 12, 2025, 07:00 ET Basking Biosciences Announces First Participants Dosed in Phase 1 Study of BB-025, a Direct-Acting Reversal Agent for Investigational Stroke Therapy BB-031
address the limitations of current stroke treatments. About BB-031BB-031 is an investigational RNA aptamer designed to inhibit von Willebrand Factor (vWF), a key mediator of platelet adhesion and thrombus formation. By precisely targeting this critical
More news about: Basking Biosciences Inc.
Nov 11, 2025, 13:53 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
medicines for patients living with serious neurological conditions, where significant unmet medical needs remain. Together, the companies will explore novel RNA-targeting treatment approaches designed to deliver transformative benefits for patients worldwide. On 13 October 2025, Lundbeck
More news about: H. Lundbeck A/S
Nov 11, 2025, 13:38 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
medicines for patients living with serious neurological conditions, where significant unmet medical needs remain. Together, the companies will explore novel RNA-targeting treatment approaches designed to deliver transformative benefits for patients worldwide. On 13 October 2025, Lundbeck
More news about: H. Lundbeck A/S
Nov 11, 2025, 09:36 ET GenomOncology Partners with Glioblastoma Foundation to Accelerate Precision Glioblastoma Brain Cancer Treatment
execution—demonstrating the platform's efficiency in critical care situations. Patient samples undergo comprehensive genomic panel testing (DNA), RNA fusion panel analysis, and whole genome sequencing methylation testing for MGMT. The project goal is for GenomOncology's platform to aggregate these
More news about: GenomOncology
Nov 11, 2025, 09:00 ET Lexogen honored as one of Austria's Top Innovative Companies 2026 by Statista and trend. magazine
clear mission: to help scientists explore how genes work by developing advanced technologies to analyze RNA, the molecule that reveals gene activity. Their complete solutions for RNA and transcriptome analysis are used worldwide by researchers. These tools support both fundamental and applied
More news about: LEXOGEN
Nov 11, 2025, 09:00 ET Lexogen honored as one of Austria's Top Innovative Companies 2026 by Statista and trend. magazine
clear mission: to help scientists explore how genes work by developing advanced technologies to analyze RNA, the molecule that reveals gene activity. Their complete solutions for RNA and transcriptome analysis are used worldwide by researchers. These tools support both fundamental and applied
More news about: LEXOGEN
Nov 11, 2025, 07:51 ET RNA Horizons 2025 in Palermo Showcases Breakthroughs Driving the Next Wave of RNA Therapeutics
"RNA Horizons 2025 highlighted the power of scientific collaboration to accelerate RNA innovation, said the RNA Horizons Organizing Committee. We are witnessing a rapid transformation from discovery science to real-world RNA therapies."
More news about: RNA Horizons
Nov 11, 2025, 07:50 ET RNA Horizons 2025 in Palermo zeigt bahnbrechende Entwicklungen für die Zukunft RNA-basierter Therapeutika
Krichevsky stellten RNA-basierte Strategien für metabolische sowie neurodevelopmentale Erkrankungen vor und zeigten das wachsende therapeutische Potenzial von RNA. Eine kooperative Zukunft „RNA Horizons 2025
More news about: RNA Horizons
Nov 11, 2025, 07:50 ET O RNA Horizons 2025 em Palermo destaca avanços que impulsionam o futuro da terapia com RNA
Krichevsky exibiram estratégias baseadas em RNA para distúrbios metabólicos e de neurodesenvolvimento, ilustrando o potencial terapêutico alargado do RNA. Um futuro colaborativo "O RNA Horizons 2025 refletiu a força da
More news about: RNA Horizons
Nov 11, 2025, 07:50 ET RNA Horizons 2025 , tenutosi a Palermo, evidenzia le innovazioni che stanno plasmando il futuro delle terapie basate sull'RNA
Due temi centrali hanno dominato le discussioni: raggiungere una stabilità duratura e una persistenza mirata dei reagenti a base di RNA – oligonucleotidi antisenso e RNA autoamplificante – e promuovere un'integrazione interdisciplinare tra ricerca di base, sviluppo clinico e applicazione a livello industriale.
More news about: RNA Horizons
Nov 10, 2025, 16:05 ET Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
DIEGO, Nov. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today reported
More news about: Avidity Biosciences, Inc.
Nov 10, 2025, 11:50 ET New England Biolabs® announces a full lineup of events supporting the AMP 2025 Annual Meeting & Expo in Boston, MA
SequencingPresenter: Kaylinnette Pinet, Ph.D. Poster #ST156: Integration of Whole-exome Sequencing and RNA-seq Facilitates Somatic Mutation Detection in Tumor Tissue SamplesPresenter: Margaret R. Heider, Ph.D.
More news about: New England Biolabs, Inc.